Skip to main content
TipRanks
Go Ultimate75% OFF

Shinpoong Pharmaceutical Co., Ltd. (019170) AI Stock Analysis

KR:019170

Shinpoong Pharmaceutical Co., Ltd.

(Korea Exchange:019170)

Select Model
Rating:40Underperform
Price Target:KRW 7,933.00â–²(0.16% Upside)
Action:initiatedcoverage
Date:11/02/26

The score is primarily supported by a sound, low-leverage balance sheet, but weakening profitability and cash generation are significant risks. Bearish technical momentum and the absence of earnings-based or dividend valuation support further constrain the outlook.

Positive Factors
Manageable LeverageModerate leverage reduces balance-sheet pressure and leaves the company better positioned to fund operations through uneven earnings periods. A sizable equity base and stable-to-growing assets also provide financial resilience, supporting flexibility for research investment and commercial activity.
Negative Factors
TTM Profitability WeaknessThe return to losses after 2025 indicates that earnings recovery is not yet durable. Sharp operating-margin compression leaves less room to absorb cost increases or revenue volatility, making near-term profits more vulnerable and reducing confidence in consistent earnings generation.

Shinpoong Pharmaceutical Co., Ltd. (019170) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%KR:019170-43.35%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
KRW 409.53B
Dividend Yield
―
Average Volume (3M)
524.13K
Price to Earnings (P/E)
-829.3
Beta (1Y)
0.31
Revenue Growth
6.21%
EPS Growth
95.65%
Country
KR
Employees
815
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Shinpoong Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Shinpoong Pharmaceutical Co., Ltd. is a South Korean company that manufactures and distributes a broad spectrum of pharmaceutical products. Its portfolio includes both cephalosporin and penicillin antibiotics, alongside other finished medications. Th...

Shinpoong Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

The balance sheet is solid, supported by modest debt and substantial equity, but weakening EBIT and EBITDA margins, a small TTM net loss, and declining free cash flow reduce the score.

Income Statement

62Positive

Balance Sheet

78Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue239.07B234.68B221.09B200.23B209.29B189.24B
Gross Profit101.27B102.37B81.80B80.28B77.97B77.39B
EBITDA14.57B25.65B-27.14M-39.81B-21.92B3.89B
Net Income-815.28M8.83B-15.39B-57.33B-35.31B-11.53B
Balance Sheet
Total Assets366.50B352.47B342.09B350.08B361.54B392.58B
Cash, Cash Equivalents and Short-Term Investments72.30B71.50B56.46B60.46B55.92B92.70B
Total Debt53.28B55.86B54.60B46.15B1.93B1.18B
Total Liabilities88.47B81.74B84.00B79.30B30.78B38.03B
Stockholders Equity277.18B269.98B256.82B269.59B329.61B353.49B
Cash Flow
Free Cash Flow13.57B13.78B-21.24B-39.88B-32.67B-76.64B
Operating Cash Flow17.57B17.25B-15.15B-24.85B-26.44B-71.03B
Investing Cash Flow-11.16B-14.71B5.58B-16.31B43.20B49.03B
Financing Cash Flow2.14B3.70B6.20B43.24B-1.87B-6.42B

Shinpoong Pharmaceutical Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price7920.00

Price Trends

50DMA9168.80Negative
100DMA8735.50Negative
200DMA9952.55Negative

Market Momentum

MACD-325.05Positive
RSI36.51Neutral
STOCH53.83Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:019170, the sentiment is Negative. The current price of 7920.00 is below the 20-day moving average (MA) of 8428.50, below the 50-day MA of 9168.80, and below the 200-day MA of 9952.55, indicating a bearish trend. The MACD of -325.05 indicates Positive momentum. The RSI at 36.51 is Neutral, neither overbought nor oversold. The STOCH value of 53.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:019170.

Shinpoong Pharmaceutical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

KR:019170 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
KR:001060KR:00106071OutperformKRW 570.85B5.64―2.75%10.50%96.29%
KR:249420KR:24942060NeutralKRW 397.47B22.91―1.59%2.12%-41.73%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
KR:009290KR:00929052NeutralKRW 294.94B24.73―1.59%5.20%-65.65%
KR:003000KR:00300050NeutralKRW 393.18B68.96―3.14%22.17%-38.54%
KR:170900KR:17090046NeutralKRW 324.63B-55.69―2.06%15.38%―
KR:019170KR:01917040UnderperformKRW 408.79B-829.32――6.21%95.65%

* General Sector Average

Performance Comparison

-50%0%50%100%150%KR:019170KR:001060KR:003000KR:009290KR:170900KR:249420Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
KR:019170 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
KR:019170Shinpoong Pharmaceutical Co., Ltd.7920.00-6670.00-45.72%
KR:001060JW Pharmaceutical Corporation23650.00-876.45-3.57%
KR:003000Bukwang Pharmaceutical Co., Ltd.3985.00211.395.60%
KR:009290Kwang Dong Pharmaceutical Co., Ltd.6270.00348.935.89%
KR:170900Dong-A ST Co., Ltd.34050.00-15589.28-31.41%
KR:249420Ildong Pharmaceutical Co., Ltd.12570.00-17877.35-58.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026